Global Cell-based Assays Market 2023

Description
Cell-based assays refer to techniques that utilize living cells to evaluate various biological processes, such as drug discovery, toxicity testing, and basic research. These assays involve the measurement of cell viability, proliferation, cytotoxicity, apoptosis, and other cellular functions. They find applications in the pharmaceutical industry, academic research labs, contract research organizations, and genomic instrumentation suppliers.

The global cell-based assays market is projected to rise by USD 12.2 billion by 2029, according to the latest market study results. It is anticipated to expand at a CAGR of 8.11 percent during the forecast period.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global cell-based assays market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors' approaches.

Market Segmentation
Product: consumables, instruments and software, services
Technology: automated handling, flow cytometry, high content screening, high-throughput screening, others
Application: basic research, drug screening, predictive toxicology, others
End user: academic research institutes, contract research organizations (CROs), pharmaceutical and biopharmaceutical companies, others
Region: Asia-Pacific, Europe, North America, RoW (Rest of World)
Consumables: assay kits, cell lines, microplates, probes and labels, reagents, others

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, technology, application, end user, and region. The global market for cell-based assays can be segmented by product: consumables, instruments and software, services. In 2022, the consumables segment made up the largest share of revenue generated by the cell-based assays market. Cell-based assays market is further segmented by technology: automated handling, flow cytometry, high content screening, high-throughput screening, others. The flow cytometry segment was the largest contributor to the global cell-based assays market in 2022. Based on application, the cell-based assays market is segmented into: basic research, drug screening, predictive toxicology, others. The drug screening segment is estimated to account for the largest share of the global cell-based assays market. On the basis of end user, the cell-based assays market also can be divided into: academic research institutes, contract research organizations (CROs), pharmaceutical and biopharmaceutical companies, others. The pharmaceutical and biopharmaceutical companies segment held the largest share of the global cell-based assays market in 2022 and is anticipated to hold its share during the forecast period. Cell-based assays market by region is categorized into: Asia-Pacific, Europe, North America, RoW (Rest of World). In 2022, North America made up the largest share of revenue generated by the cell-based assays market.

The consumables market is further segmented into assay kits, cell lines, microplates, probes and labels, reagents, others. Among these segments, the reagents category emerged as the frontrunner in 2022, capturing the largest market share. This dominance is projected to persist throughout the forecast period.

Reagents, in the context of this market, encompass a wide range of substances or compounds employed in conducting experiments on living cells to observe their biological activity. These reagents encompass not only the cells themselves but also encompass other essential materials such as culture media, growth factors, antibodies, enzymes, dyes, and various other chemicals indispensable for the assay process.

The selection of reagents utilized in a cell-based assay holds paramount importance, as it significantly impacts the accuracy and validity of the obtained results. The careful consideration and judicious employment of reagents are crucial in ensuring the reliability and reproducibility of experimental outcomes. By employing the appropriate reagents, researchers can enhance the precision and robustness of their assays, thereby facilitating more accurate interpretations and conclusions.

Major Companies and Competitive Landscape
The report explores the recent developments and profiles of key vendors in the Global Cell-based Assays Market, including Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Charles River Laboratories International, Inc., Corning Incorporated, Danaher Corporation, Enzo Life Sciences AG, Eurofins DiscoverX Corporation, Laboratory Corp of America Holdings (LabCorp), Lonza Group AG, Merck KGaA, PerkinElmer, Inc., Promega Corporation, Thermo Fisher Scientific, Inc., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Scope of the Report
To analyze and forecast the market size of the global cell-based assays market.
To classify and forecast the global cell-based assays market based on product, technology, application, end user, region.
To identify drivers and challenges for the global cell-based assays market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cell-based assays market.
To identify and analyze the profile of leading players operating in the global cell-based assays market.

Why Choose This Report
Gain a reliable outlook of the global cell-based assays market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Recent Developments
▹ PerkinElmer, Inc. acquired Cisbio Bioassays SAS from Abénex Capital SA and the management of Cisbio for approximately $220 million on April 24, 2019. As a part of consideration of $219.8 million PerkinElmer acquired cash of $12.5 million. Cisbio had about $51 million of revenue in 2018.